Related Experiment Video

Updated: Aug 24, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.8K

Transforming Stimulated Clone 22 (TSC-22) Interacts Directly with Bromodomain-Containing Protein 7 (BRD7) to Enhance

Seung-Hoon Lee1, Donchan Choi1

  • 1Department of Life Science, YongIn University, Yongin 17092, Korea.

Development & Reproduction
|October 26, 2022
PubMed

Insights

Transforming stimulated clone 22 (TSC-22) enhances bromodomain-containing protein 7 (BRD7)

Area of Science:

  • Molecular biology
  • Cancer research
  • Cellular signaling

Background:

  • Bromodomain-containing protein 7 (BRD7) is implicated in cellular processes and embryo development.
  • BRD7 exhibits tumor suppressor functions and is frequently downregulated in cancers.
  • The precise regulatory mechanisms of BRD7's tumor-suppressive activity remain incompletely understood.

Purpose of the Study:

  • To identify novel interacting partners of BRD7.
  • To elucidate the role of transforming stimulated clone 22 (TSC-22) in regulating BRD7 function.
  • To investigate the combined tumor-suppressive mechanisms of BRD7 and TSC-22.

Main Methods:

  • Co-immunoprecipitation assays to identify BRD7 interacting proteins.
  • Western blotting and quantitative PCR to assess protein and gene expression levels.
  • Analysis of the extracellular signal-regulated kinase (ERK) pathway activity.

Main Results:

  • Transforming stimulated clone 22 (TSC-22) was identified as a novel binding partner of BRD7.
  • TSC-22 acts as a positive regulator, enhancing BRD7's ability to inactivate the extracellular signal-regulated kinase (ERK) pathway.
  • The synergistic action of TSC-22 and BRD7 demonstrates potent tumor-suppressive effects.

Conclusions:

  • TSC-22 modulates BRD7 activity, revealing a new layer of regulation for this tumor suppressor.
  • The combined inactivation of the ERK pathway by BRD7 and TSC-22 underlies their synergistic anti-cancer effects.
  • Targeting BRD7 and TSC-22 pathways offers potential for novel cancer therapies.
Keywords:
Bromodomain-containing protein 7ERK pathwayOvarian cancerTransforming growth factor-β-stimulated clone-22

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K
Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.6K